Siemens Healthineers is stopping all sales of its general ultrasound systems
Siemens Healthineers is officially stopping all sales of its general ultrasound systems, effective October 12.
The announcement comes as the company shifts its ultrasound business toward cardiovascular procedures, image-guided therapy and other advanced imaging technologies. The company said the strategic move will prioritize cardiovascular interventions, AI, software development and partnerships with cardiovascular device manufacturers. Its portfolio will focus on supporting physicians performing electrophysiology and structural heart procedures, where the demand for procedural image guidance has seen significant growth in recent years.
“Medicine is evolving, and imaging is increasingly becoming part of therapy, not just diagnosis,” Sourabh Pagaria, head of Ultrasound at Siemens Healthineers, said in an announcement. “By concentrating our ultrasound portfolio on procedural imaging, we can apply our strengths in advanced cardiovascular imaging, ICE, software, AI, and partnerships with cardiovascular device companies to address important clinical needs and create long-term value for physicians, patients, and Siemens Healthineers.”
The change includes the company’s Acuson Sequoia, Redwood, Juniper and Maple systems. Siemens Healthineers will continue selling ultrasound products designed for procedural applications, including the Acuson Origin cardiovascular imaging platform, P500 intracardiac echocardiography (ICE) system and Freestyle ultrasound system, along with dedicated software and catheters.
Despite ending sales of general imaging ultrasound systems, Siemens Healthineers will continue servicing and supporting existing customers. That commitment includes maintenance, software updates and transducer availability, as well as fulfillment of contractual and regulatory obligations throughout the systems’ lifecycles.
The company noted that general imaging ultrasound is a market well served by multiple established providers. It added that its decision to leave that segment reflects a narrower business focus rather than an end to support for its installed base. It said it expects procedural imaging to offer more opportunities for long-term growth as minimally invasive treatments become increasingly important in cardiovascular care.
More information can be found here.
In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.